DOCSLIB.ORG

BIOVIA Discovery Studio

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BIOVIA Discovery Studio 3DS.COM/BIOVIA3DS.COM/BIOVIA © © DassaultDassault Systèmes Systèmes| |Confidential Confidential InformationInformation | |3/16/2019 3/16/2019| BIOVIA Discovery Discovery BIOVIA COMPREHENSIVE MODELING 創源生技 FOR FOR SCIENCESLIFE ANDSIMULATIONS 經理 陳冠文 分子視算中心 Studio (Gene) 3DS.COM/BIOVIA © Dassault Systèmes | Confidential Information | 3/16/2019 | Copyright©2019 GGA Corp., All rights reserved. AllCorp., GGA Copyright and Disclaimer • Copyright © 2019 GGA corp. All rights reserved. • This presentation and/or any related documents contains statements regarding our plans or expectations | for future features, enhancements or functionalities of current or future products (collectively "Enhancements"). Our plans or expectations are subject to change at any time at our discretion. 3/16/2019 Accordingly, GGA Corp. is making no representation, undertaking no commitment or legal obligation to create, develop or license any product or Enhancements. • The presentation, documents or any related statements are not intended to, nor shall, create any legal | Confidential Information | Information | Confidential obligation upon GGA Corp., and shall not be relied upon in purchasing any product. Any such obligation shall only result from a written agreement executed by both parties. Systèmes • In addition, information disclosed in this presentation and related documents, whether oral or written, is © Dassault Dassault © confidential or proprietary information of GGA Corp.. It shall be used only for the purpose of furthering our business relationship, and shall not be disclosed to third parties. 3DS.COM/BIOVIA Copyright©2019 GGA Corp., All rights reserved. GGA is part of the BIONET Group (訊聯生物科技) | CEO: Christopher Tsai, Ph.D. 蔡政憲 博士 3/16/2019 Established: Nov. 2008 Main Product & Service Areas: | Confidential Information | Information | Confidential 1. Genetic Testing Systèmes 2. Molecular Diagnosis © Dassault Dassault © 3. Scientific Informatics & Bio IT IPO Date: September 17, 2012 3DS.COM/BIOVIA Stock Ticker: 4160 (Taiwan OTC) Copyright©2019 GGA Corp., All rights reserved. About Dassault Systèmes | 3/16/2019 190,000 enterprise a Scientific customers 3,500 partners company • 12 industries in 140 countries | Confidential Information | Information | Confidential • >10 million on premise users • Research & Education Combining Science, Te Long-term 12,400 • >100 million online users • Software & Technology Systèmes chnology and Art for a • Sales & Services driven sustainable society passionate people • Majority shareholder control © Dassault Dassault © • 112 nationalities • Revenue: $ 2.8 Bn* • One global R&D / 53 labs • Operating margin: 31.5%* • Game changing 3DEXPERIENCE 3DS.COM/BIOVIA solutions Copyright©2019 GGA Corp., All rights* reserved. Non-IFRS 10 BIOVIA Perfect Discovery Optimize for Sustainable Discover new materials and ingredients in Performance & silico to enhance new product offerings Manufacture | Link chemical structure and 3/16/2019 3 performance, and optimize Validate trade-offs between multiple Breakthrough requirements Perfect | Confidential Information | Information | Confidential Materials 2 Discovery Systèmes Rapidly test and validate virtual material samples that may be too expensive, © Dassault Dassault © complicated, or risky to synthesize experimentally 1 3DS.COM/BIOVIA Screen Candidate Rapidly screen large volumes of molecules to find new leads, and Molecules avoid IP conflicts Copyright©2019 GGA Corp., All rights reserved. Agenda • Introduction to Predictive Science • Challenges of the Life Science Industry | • Small Molecules and Macromolecule Solution 3/16/2019 • Hands-on 基本介面操作教學 (實機演練) • Discovery Studio: Receptor-Ligand Interactions | Confidential Information | Information | Confidential 小分子化合物接合模擬 Systèmes • Hands-on操作教學 (實機演練) © Dassault Dassault © 3DS.COM/BIOVIA Copyright©2019 GGA Corp., All rights reserved. Life Sciences R&D Top Level Workflow Small | Molecule 3/16/2019 Disease Target ID and PreClinical To Clinical Biologic Selection Validation Development and ADQM | Confidential Information | Information | Confidential Systèmes Conjugate © Dassault Dassault © 3DS.COM/BIOVIA Target Target Screen “Lead “Preclinical” Hit ID Hit Validation “Hit to Lead” Identification Validation Development Optimisation” Development Copyright©2019 GGA Corp., All rights reserved. “Making” Biotherapeutics Is Different Small Molecule Biotherapeutics | 3/16/2019 | Confidential Information | Information | Confidential Systèmes Versus © Dassault Dassault © 3DS.COM/BIOVIA Chemist synthesizes the molecule Biological systems make the molecule Copyright©2019 GGA Corp., All rights reserved. Extensive experimentation, random variation and screening intrinsic to the process Biotherapeutic Discovery is Labor and Time Intensive! Select fAbs that Associate Inoculation and Create fAb phage Identify soluble bind to target Sequence fAbs sequence data tissue harvest display library fAbs (ELISA) with binding data Create full length LC | 12-20 weeks and HC plasmid constructs, store these 3/16/2019 Select top expressing Transfect E. coli w clones, test binding to plasmids, harvest cell lines that express and lyse Predictive Sciences the target | Confidential Information | Information | Confidential can reduce cycles Optimization: Systèmes and improve quality of Kinetics and Sequence the LC Affinity multiple cycles and HC from candidates to Development measurements these clones © Dassault Dassault © 9-12 months or more 3DS.COM/BIOVIA Select and store 12-20 weeks Measure expression clones that match of LC and HC by conceptual batch/clone Purify Ab Transfect HEK cells sequences Record purification details, Scale up top performing w selected To constructs, track expression levels, buffer clones Development formulation, SEC retention batch IDs (HEK time, % main peak clones) Sequencing Facility Cell Culture Lab Animal Lab Molecular Biology Lab Copyright©2019 GGAAnalytical Corp., All Lab rights reserved. Pharma And Predictive Sciences… • Example: AstraZeneca | 3/16/2019 “The right target, the right exposure, the right drug” At AstraZeneca, we’re spearheading the model-based approach to drug research and development. In our | Confidential Information | Information | Confidential mission to bring life-changing medicines to the global Systèmes population, we’re doubling our investment in Predictive © Dassault Dassault © Sciences – so we can tackle illness and disease with even more effective drugs. 3DS.COM/BIOVIA Improve Quality, Save Time, Save Money 16 Biotherapeutics Development Challenges • Examples of failures in Development include: | 3/16/2019 | Confidential Information | Information | Confidential Purification Problems Poor solubility/ Systèmes High viscosity BIOVIA Predictive Sciences Can Helpstability Identify These Problems Earlier © Dassault Dassault © Can Help to Avoid Costly Development Failures 3DS.COM/BIOVIA Immunogenicity Low thermal stability Poor serum half-life Copyright©2019 GGA Corp., All rights reserved. 3DS.COM/BIOVIA © Dassault Systèmes | Confidential Information | 3/16/2019 | Generational with 3DEXPERIENCE changes Generational Copyright©2019 Copyright©2019 GGA Corp., All rights reserved.Corp., GGA Vision: Multiscale Life Modeling & Simulation HOLISTIC & INTERDISCIPLINARY approach to apprehend the complexity of biological systems which aims at understanding the spatio-temporal | interactions between components of a cell, between cells, and their interaction with the environment. 3/16/2019 | Confidential Information | Information | Confidential Systèmes © Dassault Dassault © 3DS.COM/BIOVIA Copyright©2019 GGA Corp., All rights reserved. 3DS.COM/BIOVIA © Dassault Systèmes | Confidential Information | 3/16/2019 | What’s What’s Discovery Studio Copyright©2019 GGA Corp., All rights reserved. AllCorp., GGA Discovery Studio: A Comprehensive Portfolio Protein Virtual X-ray | docking screening 3/16/2019 Protein Stability Specialist: In-situ lead QSAR, Homology and Membrane enumera- | Confidential Information | Information | Confidential ADME and modeling Binding Proteins tion Toxicity affinity Systèmes © Dassault Dassault © Simulation Specialist: Specialist: Protein and Scaffold Ligand Antibody Quantum hopping profiling 3DS.COM/BIOVIA aggregation design Mechanics Copyright©2019 GGA Corp., All rights reserved. Protein design tool includes: 1. Advanced homology modeling tools Data Support Different 2. Protein docking and epitope detection integration Data Formats 3. pH-based protonation | 4. Protein aggregation 3/16/2019 5. Virtual mutation 6. … Rational Structure-Based Protein Design of design | Confidential Information | Information | Confidential Benefit Biologics Systèmes 1. Increase the efficiency in sample preparation © Dassault Dassault © stage Automatic 2. Epitope prediction Chemical 3. Optimize protein Molecular 3DS.COM/BIOVIA design Modelling Tools Copyright©2019 GGA Corp., All rights reserved. Science and Functionality Highlights • Template identification • Sequence alignment and analysis | • Advanced homology modeling tools 3/16/2019 • Rigorous model verification • Implicit or explicit solvent-based MD simulations • Specialist tools for Antibody modeling | Confidential Information | Information | Confidential • Antibody loop modeling and refinement Systèmes • Protein docking and epitope detection © Dassault Dassault © • Optimizing protein-protein binding affinity • Predicting and guiding protein stability 3DS.COM/BIOVIA • Managing aggregation risk • Disulfide bridge prediction • Humanization Copyright©2019 GGA Corp., All rights reserved.
Load more

Recommended publications
  • JRC QSAR Model Database
    JRC QSAR Model Database EURL ECVAM DataBase service on ALternative Methods to animal experimentation To promote the development and uptake of alternative and advanced methods in toxicology and biomedical sciences SDF - STRUCTURE DATA FORMAT: How to create from SMILES The European Commission’s science and knowledge service Joint Research Centre Directorate F Health, Consumers & Reference Materials Chemicals Safety & Alternative Methods Unit The European Commission’s science and knowledge service Joint Research Centre EUR 28708 EN This publication is a Tutorial by the Joint Research Centre (JRC), the European Commission’s science and knowledge service. It aims to provide user support. The scientific output expressed does not imply a policy position of the European Commission. Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use that might be made of this publication. Contact information Email: [email protected] JRC Science Hub https://ec.europa.eu/jrc JRC107492 EUR 28708 EN PDF ISBN 978-92-79-71294-4 ISSN 1831-9424 doi:10.2760/952280 Print ISBN 978-92-79-71295-1 ISSN 1018-5593 doi:10.2760/668595 Luxembourg: Publications Office of the European Union, 2017 Ispra: European Commission, 2017 © European Union, 2017 The reuse of the document is authorised, provided the source is acknowledged and the original meaning or message of the texts are not distorted. The European Commission shall not be held liable for any consequences stemming from the reuse. How to cite this document: Triebe
    [Show full text]
  • BIOVIA DISCOVERY STUDIO® 2016 COMPREHENSIVE MODELING and SIMULATIONS for LIFE SCIENCES Datasheet
    BIOVIA DISCOVERY STUDIO® 2016 COMPREHENSIVE MODELING AND SIMULATIONS FOR LIFE SCIENCES Datasheet ACCURATELY Drug discovery is a multi-objective optimization. Scientists have to optimize both biochemical potency and characteristics such as ADME and toxicity. The latest PREDICT LIGAND release of BIOVIA’s predictive science application, Discovery Studio®, continues the BINDING evolution of new science in its market-leading CHARMm molecular simulations engine. Built on BIOVIA Foundation™, Discovery Studio® is uniquely positioned as ENERGIES the most comprehensive, collaborative modeling and simulation application for Life Sciences discovery research. DISCOVERY STUDIO 2016 Part of the 2016 BIOVIA product release series, Discovery Studio 2016 continues to deliver key new CHARMm-based molecular simulations. NEW AND ENHANCED SCIENCE • New! Steered Molecular Dynamics: Developed and validated in academia by members of the CHARMM Developer community2,3, the CHARMM AFM (Atomic Force Microscopy) function has been included in the latest release of Discovery Studio CHARMm • Apply a pull force to a molecular system to: • Estimate the ligand binding free energy • Study the conformational details of the ligand unbinding process • Investigate protein unfolding or conformational • Major DMol3 Performance Improvement: The latest release changes of the density functional theory program DMol3, version • Two protocols have been included to enable the simulation 2016, includes dramatic performance improvements, both in of protein or protein-ligand complexes while
    [Show full text]
  • In Silico Screening and Molecular Docking of Bioactive Agents Towards Human Coronavirus Receptor
    GSC Biological and Pharmaceutical Sciences, 2020, 11(01), 132–140 Available online at GSC Online Press Directory GSC Biological and Pharmaceutical Sciences e-ISSN: 2581-3250, CODEN (USA): GBPSC2 Journal homepage: https://www.gsconlinepress.com/journals/gscbps (RESEARCH ARTICLE) In silico screening and molecular docking of bioactive agents towards human coronavirus receptor Pratyush Kumar *, Asnani Alpana, Chaple Dinesh and Bais Abhinav Priyadarshini J. L. College of Pharmacy, Electronic Building, Electronic Zone, MIDC, Hingna Road, Nagpur-440016, Maharashtra, India. Publication history: Received on 09 April 2020; revised on 13 April 2020; accepted on 15 April 2020 Article DOI: https://doi.org/10.30574/gscbps.2020.11.1.0099 Abstract Coronavirus infection has turned into pandemic despite of efforts of efforts of countries like America, Italy, China, France etc. Currently India is also outraged by the virulent effect of coronavirus. Although World Health Organisation initially claimed to have all controls over the virus, till date infection has coasted several lives worldwide. Currently we do not have enough time for carrying out traditional approaches of drug discovery. Computer aided drug designing approaches are the best solution. The present study is completely dedicated to in silico approaches like virtual screening, molecular docking and molecular property calculation. The library of 15 bioactive molecules was built and virtual screening was carried towards the crystalline structure of human coronavirus (6nzk) which was downloaded from protein database. Pyrx virtual screening tool was used and results revealed that F14 showed best binding affinity. The best screened molecule was further allowed to dock with the target using Autodock vina software.
    [Show full text]
  • Quantitative Structure-Activity Relationship and Molecular Docking
    Journal of Advanced Research (2017) 8, 33–43 Cairo University Journal of Advanced Research ORIGINAL ARTICLE Quantitative structure-activity relationship and molecular docking studies of a series of quinazolinonyl analogues as inhibitors of gamma amino butyric acid aminotransferase Usman Abdulfatai *, Adamu Uzairu, Sani Uba Department of Chemistry, Ahmadu Bello University, P.M.B. 1044, Zaria, Nigeria GRAPHICAL ABSTRACT ARTICLE INFO ABSTRACT Article history: Quantitative structure-activity relationship and molecular docking studies were carried out on a Received 4 July 2016 series of quinazolinonyl analogues as anticonvulsant inhibitors. Density Functional Theory Received in revised form 11 October (DFT) quantum chemical calculation method was used to find the optimized geometry of the 2016 anticonvulsants inhibitors. Four types of molecular descriptors were used to derive a quantita- tive relation between anticonvulsant activity and structural properties. The relevant molecular * Corresponding author. Fax: +234 (+603) 6196 4053. E-mail address: [email protected] (U. Abdulfatai). Peer review under responsibility of Cairo University. Production and hosting by Elsevier http://dx.doi.org/10.1016/j.jare.2016.10.004 2090-1232 Ó 2016 Production and hosting by Elsevier B.V. on behalf of Cairo University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 34 U. Abdulfatai et al. Accepted 15 October 2016 descriptors were selected by Genetic Function Algorithm (GFA). The best model was validated Available online 16 November 2016 and found to be statistically significant with squared correlation coefficient (R2) of 0.934, 2 adjusted squared correlation coefficient (Radj) value of 0.912, Leave one out (LOO) cross valida- 2 2 Keywords: tion coefficient (Q ) value of 0.8695 and the external validation (Rpred) of 0.72.
    [Show full text]
  • Preparing a PDB File the Protein Data Bank (PDB) Is Possibly the World’S Leading Public Source of Three-Dimensional Data for Biological Molecules (1)
    Copyright ©2006, Accelrys Software Inc. All rights reserved. Preparing a PDB File The Protein Data Bank (PDB) is possibly the world’s leading public source of three-dimensional data for biological molecules (1). As of July 2006, over 37,000 entries could be found in the PDB. Hundreds more are being added every month. Both X-ray diffraction and other solid-state techniques account for the majority of the structures. However, over 5500 NMR structures are also available. These deposited structures include proteins, peptides, nucleic acids, carbohydrates, and complexes of these molecules. Figure 1: Schematic view of the ligand-binding domain from the As a first step in a modeling project, many vitamin D receptor (PDB file 1IE9). researchers look in the PDB to find available The crystallographic waters are shown structures related to their project. Preparation of as small spheres and the bound ligand these molecules for work in the Discovery Studio is shown as a CPK model. environment is a critical process to your modeling OH efforts. H3C CH In the following steps, we will load a PDB file for 3 the ligand-binding domain of the vitamin D receptor H C 3 (VDR) in complex with a ligand (named VDX in CH 3 this exercise). The file is 1IE9 as reported by Tocchini-Valentini et al. (5). The vitamin D receptor is responsible for the expression of a H variety of genes including calcium metabolism, bone formation, and cell growth and differentiation CH 2 (2). Understanding VDR conformational changes resulting from interactions with bound ligands may HO OH help to identify and treat persons at risk for Figure 2: 1α,25-dihydroxyvitamin disorders such as osteoporosis, breast cancer, or D3, the metabolized form of prostate cancer.
    [Show full text]
  • Original Research Paper In-Silico FDA-Approved Drug Repurposing to Find
    Original Research Paper In-silico FDA-approved drug repurposing to find the possible treatment of Coronavirus Disease-19 (COVID-19) Kumar Sharp1, Dr. Shubhangi Dange2* 12nd MBBS undergraduate student, Government Medical College and Hospital, Jalgaon 2Associate Professor, Dept. of Microbiology, Government Medical College and Hospital, Jalgaon *Corresponding author: - Dr. Shubhangi Dange, Associate Professor, Department of Microbiology, Government Medical College and Hospital, Jalgaon Email: [email protected] Abstract Identification of potential drug-target interaction for approved drugs serves as the basis of repurposing drugs. Studies have shown polypharmacology as common phenomenon. In-silico approaches help in screening large compound libraries at once which could take years in a laboratory. We screened a library of 1050 FDA-approved drugs against spike glycoprotein of SARS-CoV2 in-silico. Anti-cancer drugs have shown good binding affinity which is much better than hydroxychloroquine and arbidol. We have also introduced a hypothesis named “Bump” hypothesis which and be developed further in field of computational biology. Keywords: spike glycoprotein; FDA; drug repurposing; anti-cancer; hydroxychloroquine Introduction Identification of potential drug-target interaction for approved drugs serves as the basis of repurposing drugs. Studies have shown polypharmacology as common phenomenon [1][2]. Since the three-dimensional structures of proteins of SARS-CoV2 have been mapped it opens opportunity for in-silico approaches of either novel drug discovery or drug repurposing. In the absence of an exact cure or vaccine, coronavirus disease-19 has taken a huge toll of humanity. Our study of target specific drug docking and novel hypothesis contributes in this fight. In-silico approaches help in screening large compound libraries at once which could take years in a laboratory.
    [Show full text]
  • What Is Discovery Studio?
    Discovery Studio 2.0 Accelrys Life Science Tool 林進中 分子視算 What is Discovery Studio? • Discovery Studio is a complete modelling and simulations environment for Life Science researchers – Interactive, visual and integrated software – Consistent, contemporary user interface for added ease-of-use – Tools for visualisation, protein modeling, simulations, docking, pharmacophore analysis, QSAR and library design – Access computational servers and tools, share data, monitor jobs, and prepare and communicate their project progress – Windows and Linux clients and servers Accelrys Discovery Studio Application Discovery Studio Pipeline ISV Materials Discovery Accord WeWebbPPortort Pipeline ISV Materials Discovery Accord (web Studio Studio (web PilotPilot ClientClient Studio Studio ClientsClients access) (Pro or Lite ) (e.g., Client Client access) (Pro or Lite ) (e.g., Client Client Spotfire) Spotfire) Client Integration Layer SS c c i iT T e e g g i ic c P P l la a t t f f o o r r m m Tool Integration Layer Data Access Layer Cmd-Line Isentris Chemistry Biology Materials Accord Accord IDBS Oracle ISIS Reporting Statistics ISV Tools Databases Pipeline Pilot - Data Processing and Integration • Integration of data from multiple disparate data sources • Integration of disparate applications – Third party vendors and in- house developed codes under the same environment Pipeline Pilot - Data Processing and Integration • Automated execution of routine processes • Standardised data management • Capture of workflows and deployment of best practice Interoperability
    [Show full text]
  • Introduction to Biovia Discovery Studio
    Introduction to Biovia Discovery Studio 1 Introduction Discovery Studio is a suite of software for simulating small molecule and macromolecule systems. It is developed and distributed by Dassault Systemes BIOVIA (formerly Accelrys). It is a comprehensive software suite for analyzing and modeling molecular structures, sequences, and other data of relevance to life science researchers. The product includes functionality for viewing and editing data along with tools for performing basic data analysis. The Discovery Studio Visualizer is a free viewer that can be used to open data generated by other software in the Discovery Studio product line. It is designed to offer an interactive environment for viewing and editing molecular structures, sequences, X-ray reflection data, scripts, and other data. 2 It also provides a rich set of viewers for displaying plots and other graphical representations of data. The application runs on Windows and Linux and is a fully integrated desktop environment that provides access to standard operating system features such as the file system, clipboard, and printing services. Scope Discovery Studio provides software applications covering the following areas: • Simulations – Including Molecular Mechanics, Molecular Dynamics, Quantum Mechanics – For molecular mechanics based simulations: Include implicit and explicit-based solvent models and membrane models 3 – Also includes the ability to perform hybrid QM/MM calculations • Ligand Design – Including tools for enumerating molecular libraries and library optimization
    [Show full text]
  • In Silico Analysis, Modeling, Docking and Pharmacophore Studies of Proteins Involved in Auto Immune Maladies (Rheumatoid Arthritis)
    Sahithi, et al. Int J Pharm 2015; 5(3): 953-960 ISSN 2249-1848 International Journal of Pharmacy Journal Homepage: http://www.pharmascholars.com Research Article CODEN: IJPNL6 IN SILICO ANALYSIS, MODELING, DOCKING AND PHARMACOPHORE STUDIES OF PROTEINS INVOLVED IN AUTO IMMUNE MALADIES (RHEUMATOID ARTHRITIS) G. Prathima1*, Dr. A. Ravindernath2, Dr. P. Raja Rao 3, P. Sahithi 4 1*M.Tech Biotechnology Final year, University College of Technology, Osmania University, Hyderabad, India 2 Professor and Head, University College of Technology, Osmania University, Hyderabad, India 3 Associate Professor, University College of Technology, Osmania University, Hyderabad, India 4Assistant Professor, University College of Technology, Osmania University, Hyderabad, India *Corresponding author e-mail: [email protected] ABSTRACT Cytokine networks participate with paracrine and autocrine loops maintaining cellular activation in the synovial intimal lining. In rheumatoid arthritis inflammatory changes occur throughout the connective tissues of the body. The most useful medications in relieving the pain and disability of rheumatoid arthritis with anti-inflammatory properties are aspirin and ibuprofen. The present project was focused on study of anti-rheumatoid arthritis activity of bioactive compounds.In the present study, homology modeling, mutagenesis, docking studies were carried out with some of the selected bioactive compounds.PDB latest version was used to identify the target protein, obtain sequence from protein sequence data bank and homology modeling for the target protein was done using modeler 9.14 version and MOE 2008. version. Docking studies using molecular operating environment program revealed that Ellagic acid, Curcuminoid and Methyl gallate possess anti rheumatoid arthritis activity. Further, pharmacophore mapping studies were performed using DISCOVERY STUDIO on these compounds in order to identify the pharmacophoric feature responsible for the observed activity of the compounds.
    [Show full text]
  • Molecular Dynamics Simulation Study of the Selectivity of a Silica Polymer for Ibuprofen
    International Journal of Molecular Sciences Article Molecular Dynamics Simulation Study of the Selectivity of a Silica Polymer for Ibuprofen Riccardo Concu * and M. Natalia D. S. Cordeiro * REQUIMTE/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Rua do Campo Alegre, 687, 4169-007 Porto, Portugal * Correspondence: [email protected] (R.C.); [email protected] (M.N.D.S.C.); Tel.: +351-220-402-502 (R.C. & M.N.D.S.C.) Academic Editor: Humberto González-Díaz Received: 19 May 2016; Accepted: 28 June 2016; Published: 7 July 2016 Abstract: In the past few years, the sol-gel polycondensation technique has been increasingly employed with great success as an alternative approach to the preparation of molecularly imprinted materials (MIMs). The main aim of this study was to study, through a series of molecular dynamics (MD) simulations, the selectivity of an imprinted silica xerogel towards a new template—the (˘)-2-(P-Isobutylphenyl) propionic acid (Ibuprofen, IBU). We have previously demonstrated the affinity of this silica xerogel toward a similar molecule. In the present study, we simulated the imprinting process occurring in a sol-gel mixture using the Optimized Potentials for Liquid Simulations-All Atom (OPLS-AA) force field, in order to evaluate the selectivity of this xerogel for a template molecule. In addition, for the first time, we have developed and verified a new parameterisation for the Ibuprofen® based on the OPLS-AA framework. To evaluate the selectivity of the polymer, we have employed both the radial distribution functions, interaction energies and cluster analyses. Keywords: molecular dynamics; ibuprofen; molecular imprinting; xerogels; sol-gel; GROMACS; OPLS-AA 1.
    [Show full text]
  • Molecular Docking Studies of Some Tetrahydronaphtalene-Benzimidazole Derivatives and Correlation with Their Corresponding Anti-Mrsa Activities
    J. Fac. Pharm. Ankara / Ankara Ecz. Fak. Derg., 43(1): 20-27, 2019 Doi: 10.33483/jfpau.519907 ORIGINAL ARTICLE / ÖZGÜN MAKALE MOLECULAR DOCKING STUDIES OF SOME TETRAHYDRONAPHTALENE-BENZIMIDAZOLE DERIVATIVES AND CORRELATION WITH THEIR CORRESPONDING ANTI-MRSA ACTIVITIES YENİ TETRAHİDRONAFTALEN-BENZİMİDAZOL TÜREVİ BİLEŞİKLERİN MOLEKÜLER DOKİNG ÇALIŞMALARI VE ONLARIN ANTİ-MRSA AKTİVİTELERİNİN KARŞILAŞTIRILMASI Fikriye ZENGİN, Mehmet Murat KIŞLA*, Zeynep ATEŞ-ALAGÖZ Ankara University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Ankara, Turkey. ABSTRACT Objective: Methicillin- resistant S. aureus (MRSA) is a type of bacteria which is resistant to various types of antibiotics and causes mortality in hospital environment and community. To further investigate the inhibition activity of previously synthesized retinoidal compounds against MRSA, docking studies of these compounds with MRSA pyruvate kinase (PK) were made. Material and Method: As a first step, ligand preparation procedure has been made. For optimization of compounds, Hyperchem Professional was used. Molecular Mechanics Force Field (MMFF) and semi-empirical methods have been implemented in this program. After converting the ligands to pdb files, charges and torsions were added via AutoDockTools 1.5.6. Macromolecule file for MRSA Pyruvate kinase (PDB ID:3T07) was procured from protein data bank. Appropriate chain for binding was chosen via UCSF Chimera. Polar hydrogens and Gasteiger charges were added to macromolecule via AutoDockTools 1.5.6. Gridbox has been predicted by protein- ligand complex which is currently present in protein data bank and prepared via same software. Docking process was made via AutoDock Vina. For MIC values of retinoidal compounds, previous study by Ates-Alagoz et al. has been used. In addition, some QSAR properties were calculated via Hyperchem Professional and were also interpreted.
    [Show full text]
  • Molecular Docking Study of Primaquine-Favipiravir Based Compounds As Potential Inhibitors of COVID-19 Main Protease
    European Reviews of Chemical Research, 2020, 7(1) Copyright © 2020 by Academic Publishing House Researcher s.r.o. Published in the Slovak Republic European Reviews of Chemical Research Has been issued since 2014. E-ISSN: 2413-7243 2020, 7(1): 3-15 DOI: 10.13187/ercr.2020.1.3 www.ejournal14.com Articles Molecular Docking Study of Primaquine-Favipiravir Based Compounds as Potential Inhibitors of COVID-19 Main Protease Olawale F. Akinyele a, Emmanuel G. Fakola a, Oluwatoba E. Oyeneyin b , *, Omolara O. Adeboye с, Ayowole O. Ayeni a, Justinah S. Amoko d, Temitope A. Ajayeoba a a Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria b Adekunle Ajasin University, Akungba-Akoko, Ondo State, Nigeria с Emmanuel Alayande College of Education, Oyo, Oyo State, Nigeria d Adeyemi College of Education, Ondo, Ondo State, Nigeria Abstract The continuous search for drugs that can combat COVID-19 virus is very important in a bid to save lives and address failing economies. Schiff bases and amide compounds derived from the fusion of primaquine (a 4-aminoqinoline antimalarial) and favipiravir are hereby reported because of suitable synthetic approaches and are investigated for their potential as drug candidates against the virus. The molecular docking results using iGEMDOCK and LeDock showed that the compounds had better interaction with the protease protein of the coronavirus (6LU7) as they displayed better scores than the standard drugs used in the study (chloroquine and favipiravir). The high binding affinity could be as a result of the fusion of both drug candidates. The docking results were analyzed using Discovery Studio and PyMOL.
    [Show full text]